Aubrak Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $15.8M

  • Investors
  • 5

Aubrak Therapeutics General Information

Description

Researcher and developer of new drugs using innovation biotechnology. The company focuses on the development of new anti-cancer drugs such as small molecule targeted protein degraders (PROTAC and molecular glue), enabling patients with drugs designed for unmet clinical need.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 393, Block A, Phase I, Zhongdan Ecological Life Science Industrial Park
  • No. 3-1, Xinjinhu Road, Jiangbei New District
  • Nanjing, Jiangsu
  • China
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Room 393, Block A, Phase I, Zhongdan Ecological Life Science Industrial Park
  • No. 3-1, Xinjinhu Road, Jiangbei New District
  • Nanjing, Jiangsu
  • China

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aubrak Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC 25-Mar-2022 $15.8M Completed Clinical Trials - General
To view Aubrak Therapeutics’s complete valuation and funding history, request access »

Aubrak Therapeutics Patents

Aubrak Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024165050-A1 Proteolysis-targeting chimera (protac) compounds and uses thereof field Inactive 10-Feb-2023
WO-2022048605-A1 Heterocyclic compound, preparation method therefor, intermediate, composition, and applications Inactive 04-Sep-2020
WO-2022048605-A8 Heterocyclic compound, preparation method therefor, intermediate, composition, and applications Inactive 04-Sep-2020 C07D401/14

Aubrak Therapeutics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Eastern Biopharmaceuticals Corporation Minority
Ennovation Ventures Venture Capital Minority
Hermed Capital Venture Capital Minority
Nanjing Jiangbei New Area Innovation Investment Fund Management PE/Buyout Minority
Realharmony Capital Venture Capital Minority
To view Aubrak Therapeutics’s complete investors history, request access »

Aubrak Therapeutics FAQs

  • When was Aubrak Therapeutics founded?

    Aubrak Therapeutics was founded in 2021.

  • Where is Aubrak Therapeutics headquartered?

    Aubrak Therapeutics is headquartered in Nanjing, China.

  • What industry is Aubrak Therapeutics in?

    Aubrak Therapeutics’s primary industry is Drug Discovery.

  • Is Aubrak Therapeutics a private or public company?

    Aubrak Therapeutics is a Private company.

  • What is Aubrak Therapeutics’s current revenue?

    The current revenue for Aubrak Therapeutics is .

  • How much funding has Aubrak Therapeutics raised over time?

    Aubrak Therapeutics has raised $15.8M.

  • Who are Aubrak Therapeutics’s investors?

    Eastern Biopharmaceuticals, Ennovation Ventures, Hermed Capital, Nanjing Jiangbei New Area Innovation Investment Fund Management, and Realharmony Capital have invested in Aubrak Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process